Also listed under Neoplasms, Mesothelial
Mesothelioma clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-14
What changed in the last 30 days
11 trials changed in the last 30 days: 1 stopped, 5 with notable changes, 5 with minor changes only.
- Minor: NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Stopped: CT-95 in Advanced Cancers Associated With Mesothelin Expression Trial terminated
- Notable: RAINFOL-01 · Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Primary completion pushed from Jul 2027 to Dec 2028
- Notable: ABILITY-1 · Beta-only IL-2 ImmunoTherapY Study Primary completion pushed from Nov 30, 2026 to Oct 20, 2028
- Minor: Hemithoracic Arc Radiotherapy Post Pleural Decortication Trial completed
- Notable: Mesothelin-targeted CAR T-cell Therapy · Mesothelioma Primary and study completion pushed from Sep 30, 2026 to Sep 30, 2027
- Notable: Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Recruitment opened
- Minor: TEADCO · 2-part Phase 1/2 Open-label Trial on ODM-212 Trial sites expanded: 2 → 23 locations
- Minor: KFA115 Alone and in Combo With Pembrolizumab · Select Advanced Cancers Primary and study completion pushed from Sep 1, 2027 to Oct 5, 2027
- Notable: Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome Primary and study completion pushed from Jul 1, 2026 to Jul 1, 2027
- Minor: MDX2001 · Advanced Solid Tumors Enrollment increased: 285 → 330 participants
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-23 | NCT07892300 Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer | Oliver Jonas new | Early Phase 1 |
| 2026-10-09 | NCT07869056 Forceps Versus Cryobiopsy in Undiagnosed Exudative Pleural Effusion Using Rigid… | Ahmed Zakaria Elsaeed new |
Active trials by phase
| Early Phase 1 | 2 | |
| Phase 1 | 36 | |
| Phase 1/2 | 28 | |
| Phase 2 | 36 | |
| Phase 3 | 3 |
Not charted: 36 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
National Cancer Institute (NCI) (14) · Memorial Sloan Kettering Cancer Center (9) · A2 Biotherapeutics Inc. (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Novartis Pharmaceuticals (3) · Abramson Cancer Center at Penn Medicine (2) · AstraZeneca (2) · Brigham and Women's Hospital (2) · Dana-Farber Cancer Institute (2) · Fudan University (2)
Get alerts when Mesothelioma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.